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Immunosuppressive Therapy and Tolerance of Organ Allografts 
Thomas E. Starzl, M.D., Ph.D. 
In this issue of the Journal, three articles describe 
several organ-transplant recipients in whom al-
lografts have maintained good function for up 
to 5 years without immunosuppressive treat-
ment.1-3 In two articles concerning combined 
kidney and hematopoietic stem-cell transplanta-
tion, the authors attributed the successful out-
come in their patients to the cotransplantation 
of donor stem cells.1 ,2 
The third report, by Alexander et aI., con-
cerns a young girl who received a completely 
HLA-mismatched liver from a deceased male 
donor but did not receive a donor stem-cell in-
fusion. 3 The cause of the fulminant hepatic fail-
ure with which the patient presented was never 
firmly established. However, a viral infection was 
thought to have caused lymphopenia that was 
noted at the initial hospital admission and per-
sisted for a half year after liver transplantation. 
During the post-transplantation phase, passen-
ger leukocytes from the graft largely replaced the 
recipient's leukocytes. In addition to the presence 
of male chromosomes in leukocytes from the girl's 
blood, the recipient's RhD-negative blood sub-
group switched to the RhD-positive blood sub-
group of the donor. Severe hemolytic anemia, 
which developed 10 months after transplantation, 
was attributed to anti-RhD antibodies produced 
against the donor's RhD-positive erythrocytes by 
residual B cells in the recipient. This condition 
prompted the patient's physicians to discontinue 
all immunosuppressive therapy so that the donor's 
hematopoietic cells might eliminate all of the 
recipient's residual B cells. The net effects of this 
action were resolution of the patient's hemolytic 
anemia and retention of the graft without im-
munosuppression. 
In one article concerning combined kidney 
and hematopoietic stem-cell transplantation, re-
ported by Scandling et a1.,l tolerance was 
thought to be due to the stem-cell cotransplan-
tation. The recipient of a kidney from an HLA-
matched brother began to receive cyclosporine 
at the time of renal transplantation. During the 
next 2 weeks, he received 10 doses of total lym-
phoid irradiation, 5 doses of antithymocyte glob-
ulin, and a 10-day course of prednisone. On post-
operative day 14, he received an infusion of donor 
hematopoietic stem cells, and a I-month course 
of mycophenolate mofetil was initiated. Within 
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1 month after transplantation and consistently 
thereafter, the proportions of donor and recipi-
ent cells in the recipient's blood were about equal; 
however, there was a wide range (5 to 85%) in 
lineage subgroups. The finding of T-cell-recep-
tor excision circles - an indication of newly 
minted T cells - suggested that donor-type 
lymphocytes in the recipient were of thymic ori-
gin. Immunosuppressive therapy was discontin-
ued 6 months after transplantation, with main-
tenance of good renal function 34 months after 
transplantation. 
In the other article related to cotransplanta-
tion, Kawai et aU performed simultaneous kidney 
and stem-cell-enriched leukocyte transplanta-
tions from five HLA single-haplotype mismatched 
living related donors (three parents and two sib-
lings) into recipients who had received a condi-
tioning regimen with multiple agents.4 One pa-
tient rejected the kidney. The other four patients 
had undefined spontaneously reversible or corti-
costeroid-responsive "capillary leak" phenomena, 
which presumably were rejection episodes; never-
theless, immunosuppressive therapy was discon-
tinued in the four recipients 9 to 14 months af-
ter transplantation, without deterioration in the 
function of the grafts during 2.0 to 5.3 years of 
follow-up. There was no evidence of leukocyte 
chimerism in any patient for more than 21 days. 
Since only blood samples were studied, assess-
ment of the presence of small numbers of donor 
leukocytes (microchimerism) outside the blood 
circulation was not possible. The presence of 
suppressor T cells could explain the results, but 
no direct evidence of regulatory T cells with im-
munosuppressive activity was reported. 
The explanation that links the three articles 
begins with the description of blood-cell chime-
rism in freemartin cattle that inspired Burnet'sS 
clonal selection theory and led to the demonstra-
tion of the induction of immunologic tolerance 
in chimeric neonatal mice by Billingham, Brent, 
and Medawar.6 These kinds of experiments, and 
others performed in irradiated adult mice, showed 
that allogeneic leukocytes that persist in the re-
cipient because they cannot be rejected by a weak, 
or deliberately weakened, immune system are as-
sociated with donor-specific immune tolerance. 
The seminal requirement for the leukocyte en-
graftment is enfeeblement of the recipient's im-
mune system before transplantation. 
By contrast, after 1962, the protocols for organ 
transplantation in humans called for weakening 
of the recipient's immune system by immuno-
suppressive drugs after rather than before trans-
plantation. There was an implied commitment 
to lifetime immunosuppressive therapy. Almost 
all of the experimental and clinical observations 
in the fields of bone marrow and organ trans-
plantation since 1962 that involved drug immu-
nosuppression were presaged by the discoveries 
of Schwartz and Dameshek in 19587 and 1959.8 
Their research showed that in rabbits, 6-mer-
captopurine inhibited the immune response to a 
foreign albumin, and second and third albumin 
injections given without further 6-mercaptopu-
rine treatment did not induce a typical anam-
nestic response. 
These simple experiments yielded the first 
evidence of the importance of dose, type, and 
timing of immunosuppressive therapy, and they 
provided insight into the importance of the dose, 
type, timing, route, and localization of foreign 
antigens. Consistent with the albumin experi-
ments, lifetime tolerance in transplantation mod-
els was later accomplished with a judiciously 
timed short course of immunosuppressive ther-
apy, and it was accomplished in selected models 
without any treatment.9•13 
Such experimental results, and the occasion-
al examples of human organ recipients who 
have successfully discontinued immunosuppres-
sive treatment,9-l3 have not been viewed as toler-
ance,4 because engraftment was accomplished 
without a leukocyte infusion or cytotoxic treat-
ment of the recipient. The theory that organ en-
graftment occurs by means of mechanisms that 
are independent of chimerism remained unchal-
lenged until 1992. 
In 1992, all 30 recipients of long-surviving 
human kidney and liver allografts were observed 
to have multilineage donor-leukocyte microchi-
merism (<1% donor cells). The sparse donor cells 
were detected less frequently (in 20 to 25% of 
patients) in blood than in tissues. It was postu-
lated that the microchimerism observed in these 
patients, in some cases 30 years after transplan-
tation, was a prerequisite for maintaining the 
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Figure 1. Schematic of the Kinetics of the Development of Variable Donor-Specific Tolerance. 
Panel A shows the development of different stable balances between the quantity of persisting donor leukocytes 
that migrate to host lymphoid organs and the number of antidonor T cells produced at these sites in the organ re-
cipients described in this issue of theJournal. "3 The greatest opportunity for clonal exhaustion-deletion of the anti-
donor response is during the first few days or weeks of maximal leukocyte migration. The gray dashed curve depicts 
the graft-versus-host (GVH) reaction mounted by immune-competent donor cells that also must be exhausted and 
deleted. Stabilizing factors may include immunoregulatory cells. antibodies. endogenous molecules. or ongoing 
maintenance immunosuppressive therapy. Panel B shows the immune responses that occur simultaneously after 
transplantation. To the extent that reciprocal clonal exhaustion-deletion is not accomplished. one cell population 
will destroy the other. Solid lines depict the host-versus-graft (HVG) reactions. and dashed lines the GVH reac-
tions. Failure to achieve engraftment with the aid of immunosuppressive therapy implies the inability to control one 
or both of these responses. Adverse immune events occurred in the patients. but they were reversible. 
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state of clonal exhaustion-deletion that was 
achieved at the time of transplantation.9 -11 Find-
ings from experiments that provide strong sup-
port for this concept have recently been pub-
lished.13 ,14 
Zinkernagel and I have proposed that all out-
comes of organ or bone marrow transplantation 
are determined by the balance between the num-
ber of leukocytes that travel to lymphoid organs 
and the number of donor-specific T cells pro-
duced at those sites.lo The movement of donor 
leukocytes between lymphoid and non lymphoid 
compartments in the recipient governs both re-
sponsiveness and unresponsiveness to the allo-
graft.1o I believe that in the four patients with 
surviving allografts described by Kawai et aI., 
there is persistent microchimerism just above 
the threshold required to maintain the clonal 
exhaustion-deletion that occurred in the first 
few weeks, when within the recipient there was 
massive migration of passenger leukocytes derived 
from the graft plus the infused hematopoietic 
stem cells (Fig. lA). More donor cells (macro-
chimerism) were evident in the recipients described 
by Scandling et al. and by Alexander and col-
leagues (Fig. lA). 
Recipients of organ allografts usually receive 
large doses of immunosuppressive therapy during 
the early period of maximal leukocyte migration. 
These large doses may erode the mechanism of 
tolerance by clonal exhaustion-deletion, and they 
may preclude the goal of minimal dependence 
on (or independence from) long-term immuno-
suppressive treatment.ll To avoid this conse-
quence, two principles have been advocated for 
application singly or in combination: pretreat-
ment of the recipient and the administration of 
the least possible amount of immunosuppressive 
medication after transplantation. One or both 
principles were applied in the care of the patients 
described in the three articles in this issue of 
the Journal, either fortuitously or as a planned 
component or components of treatment. 
Zinkernagel and I have proposed that mecha-
nisms of immune reactivity and nonreactivity, 
their regulation by leukocyte migration and lo-
calization, and potential means of therapeutic 
manipulation can be generalized.lo,ll The rela-
tionship of transplantation to the immunologic 
aspects of infection, oncology, and other fields 
has been obscured, however, by the characteris-
tic double-immune reaction of transplantation. 
In this reaction, the responses of donor and re-
cipient immune cells, each to the other, result 
in reciprocal clonal expansion followed by mu-
tual clonal deletion (Fig. IB).9-13 If this process 
does not occur, the result is rejection or graft-
versus-host disease.10-l2 The recipient of an HLA-
identical kidney reported by Scandling et aI. 
reached the kind of stable coexistence of nearly 
equal donor and recipient leukocyte populations 
that has been very difficult to achieve while 
avoiding the risk of graft-versus-host disease 
with any donor other than those who are histo-
compatible. 
The results reported in all three articles are 
consistent with the axiom that organ engraft-
ment is a form of variable tolerance, the com-
pleteness of which can be crudely estimated by 
the need for maintenance immunosuppressive 
therapy.13 In all six patients, this need reached 
zero. The presumed balance between donor cells 
and antidonor T cells in the patients described 
by Kawai et al. is extremely close. It resembles 
the balance in recipients with partial tolerance 
or those who are not receiving immunosuppres-
sive therapy; this balance can be produced with 
pretreatment with anti-T-cell antibodies and 
minimal post-transplantation immunosuppres-
sive therapy.1l-13 It appears that all six recipients 
are analogous to asymptomatic carriers of intra-
cellular (non cytopathic) microbes.lo,ll Perhaps it 
will be possible to systematically achieve stable 
organ engraftment with very low dependence on 
- or in some cases complete freedom from -
long-term treatment. To do so will require just 
the right dose and timing of immunosuppres-
sive therapy with or without the aid of adjunct 
hematopoietic stem cells. 
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Cost Sharing for Health Care - Whose Skin? Which Game? 
Peter B. Bach, M.D .. MAP.P. 
In this issue of the Journal, Trivedi and colleagues1 
examine the effect of cost sharing on the use of 
screening mammography among women enrolled 
in Medicare managed-care plans from 2001 to 
2004. Focusing on more than 350,000 women 
between the ages of 65 and 69 years, the authors 
show that cost sharing - either in the form of 
copayments (in which patients pay flat fees when 
they receive services) or coinsurance (in which pa-
tients pay a fixed percentage of the cost of those 
services) - reduces the number of women who 
undergo mammography. The effects are large rela-
tive to the modest cost burdens the plans impose. 
The authors estimate that cost sharing on the or-
der of $10 to $20 reduces by 8% the proportion of 
women who undergo mammography. 
Their findings are robust, with similar find-
ings in unadjusted analyses and in multivariable 
analyses adjusted for potential demographic and 
regional confounders. Likewise, they are consis-
tent between their cross-sectional comparisons 
(i.e., between plans) and longitudinal comparisons 
(i.e., the change over time within a plan before and 
after cost sharing was instituted). Their findings 
are also broadly consistent with other analyses 
of cost sharing for cancer screening.2 The authors 
conclude that cost sharing should be waived for 
mammography, essentially because mammogra-
phy is beneficial, and therefore reducing its use by 
imposing out-oE-pocket costs is against the in-
terest of public health.3 
Their conclusion raises a challenging health 
policy question: How, if at all, should cost shar-
ing be incorporated into the design of health in-
surance? Specifically, what is the best way to struc-
ture financial incentives so that patients use 
health care services wisely but not excessively 
- or, in colloquial terms, what kind of "skin in 
the game" best serves the interest of patients with-
in the fiscal constraints of the health care system?4 
At the extremes, approaches to cost sharing 
differ in many respects. At one end are high-
deductible plans that are linked to savings ac-
counts, such as health savings accounts. In these 
plans, patients are placed in the same position as 
consumers of other goods or services. The ex-
pectation that patients will consume health care 
services wisely and sparingly because they are 
using their own money, rather than funds from 
insurers or taxpayers, is a key assumption of high-
deductible plans. Other anticipated benefits are 
that patients will take more responsibility for 
their own health and will seek high-quality and 
efficient providers, in both cases because they 
will save money by doing SO.5 Because of these 
expected benefits, economists and policymakers 
who believe in market-based solutions often cham-
pion high-deductible plans.6 
At the other end of the spectrum is "value-
based insurance" design, in which third-party 
insurers use cost sharing to induce patients to 
seek higher-value services in preference to lower-
value services. To encourage the use of beneficial 
services, insurers lower cost sharing. Conversely, 
insurers increase cost sharing when they want to 
discourage the use of undesirable services or those 
that provide little benefit. For instance, the pro-
posal to eliminate copayments for angiotensin-
converting-enzyme inhibitors for Medicare pa-
tients with diabetes is a "value-based" proposition. 
A recent study showed that when copayments are 
waived, adherence increases, resulting in both re-
duced total costs for diabetes care and improved 
diabetes outcomes? The RAND Health Insurance 
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